Abstracts tagged "Vasculitis"

Abstract Number: 1695 • ACR Convergence 2024
Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Peter Merkel¹, Arathi Setty², Ricardo Blanco-Alonso³, Ravi Suppiah⁴, Thomas Daikeler⁵, Valerie Devauchelle⁶, Elisabeth Brouwer⁷, Hiromichi Tamaki⁸, Liu Meng², Yang Yang², Avani Joshi², Charles Phillips², Peter K. Wung² and Cristina Ponte⁹, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie, North Chicago, IL, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Health New Zealand, Te Toka Tumai Auckland, Auckland, New Zealand, ⁵university hospital, Basel, Switzerland, ⁶UBO, Brest, France, ⁷University Medical Center Groningen, Groningen, Netherlands, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Giant cell arteritis (GCA) is a chronic systemic vasculitis with limited targeted therapeutic options. The recent SELECT-GCA phase 3 trial demonstrated a favorable benefit-risk…
Abstract Number: 2496 • ACR Convergence 2024
Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: We aimed to investigate the relationship between hydralazine and any form of vasculitis (small, medium, or large vessel), to describe clinical features and outcomes…
Abstract Number: 2520 • ACR Convergence 2024
Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Peter Merkel¹, Yi Peng², Patrick Zueger², Clara Ziadeh³, Ana B. Romero⁴, Richard Thielen³ and Denise Kruzikas³, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc, North Chicago, IL, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis affecting individuals aged ≥50 years. Over 80% of patients with GCA are aged ≥70 years, reflecting a…
Abstract Number: 0720 • ACR Convergence 2024
Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care
javier Merayo Chalico¹, Ana Sarahí Mulia-Soto², María Espinosa-León³, Victor Pimentel-Quiroz⁴, Ana Barrera-Vargas³ and Andrea Hinojosa-Azaola³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁴Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru
Background/Purpose: Systemic vasculitides comprise a group of inflammatory diseases involving multiple organ systems, significantly affecting various aspects of a patient's life, including their sexuality. Sexual…
Abstract Number: 0756 • ACR Convergence 2024
Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis
Ali Raza Khan¹, Nouman Shafique², Abdul Qadeer¹ and zaigham Shaukat¹, ¹Nishtar Medical University, Multan, Punjab, Pakistan, ²AdventHealth Orlando, Orlando, FL
Background/Purpose: Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) are different manifestations of the same disease process. GCA is a vasculitis that affects large and…
Abstract Number: 0855 • ACR Convergence 2024
Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study
Alexandra Kachaner¹, Arthur Mageau¹, Tiphaine Goulenok², Chrystelle Francois², Marie-Paule Chauveheid², Thomas Papo¹ and Karim Sacré¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Susac syndrome (SuS) is an exceedingly rare microvasculopathy of the brain, retina and inner ear affecting young patients with potential lifelong sequelae. No randomized controlled…
Abstract Number: 1617 • ACR Convergence 2024
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Luigi Boiardi¹, Pierluigi Macchioni¹, Francesco Muratore², Chiara Marvisi¹, Caterina Ricordi¹, Annibale Versari¹, Giulia Besutti¹, Lucia Spaggiari¹, Stefania Croci¹ and Carlo Salvarani¹, ¹Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, ²Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
Abstract Number: 1884 • ACR Convergence 2024
VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach
Stephen Williams, Stephanie Garner and Aurore Fifi-Mah, University of Calgary, Calgary, AB, Canada
Background/Purpose: The vasculitides are rare but serious conditions that are characterized by the destructive inflammation of the blood vessels. Patients living with vasculitis are often considered…
Abstract Number: 2497 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³, Ansaam Daoud⁴, Loai Dweik⁵, Hashim Syed⁶ and Omer Pamuk⁷, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵Cleveland Clinic Akron General Internal Medicine, Akron, OH, ⁶Case Western/ UH, Cleveland, ⁷University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem. There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…
Abstract Number: 2521 • ACR Convergence 2024
Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis
Michael Putman¹, Nader Khalidi², Carol Langford³, Curry Koening⁴, Christian Pagnoux⁵, David Cuthbertson⁶, Carol McAlear⁷ and Peter Merkel⁷, and the Vasculitis Clinical Research Consortium (VCRC), ¹The Medical College of Wisconsin, Milwaukee, WI, ²McMaster University, Hamilton, ON, Canada, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶University of South Florida, Tampa, FL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Macrophages play a central role in the pathogenesis of giant cell arteritis (GCA), but few studies have correlated macrophage phenotype or topography from temporal…
Abstract Number: 0724 • ACR Convergence 2024
Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Salma Al Fazazi³, Vanesa Calvo-Rio⁴, Mónica Renuncio-García⁵, Adrián Martín-Gutiérrez⁶, Amparo Sánchez-López⁷, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁷, Maria Rodríguez-Vidriales¹ and Ricardo Blanco-Alonso⁸, ¹Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, ³Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…
Abstract Number: 0757 • ACR Convergence 2024
Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis
Anna Kernder¹, Lena Noack¹, Adina Morar¹, Lara Burg², Torsten Lowin¹, Dennis Bleck¹, matthias schneider¹, Jörg Distler³, Georg Pongratz⁴ and Valentin S. Schäfer⁵, ¹Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Düsseldorf, Germany, ²Department of Rheumatology and Clinical Immunology, Clinic of Internal Medicine III, University Hospital of Bonn, Germany, Bonn, Germany, ³Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, ⁴Clinic for Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Regensburg, Germany, ⁵University Hospital Bonn, Bonn, Germany
Background/Purpose: The immunopathogenesis of giant cell arteritis (GCA) remains unclear. It is known that monocytes are recruited from peripheral blood, infiltrate the vessel wall, and…
Abstract Number: 0916 • ACR Convergence 2024
Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
Mahmut Kaymakci¹, Anuya Natu², Clifford Csizmar², Terra Lasho², Christy Finke², Abhishek Mangaonkar¹, Aref Al-Kali¹, Hassan Alkhateeb¹, Jenna Fernandez², Matthew Koster¹, Cornelia Weyand², Mrinal Patnaik¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
Abstract Number: 1620 • ACR Convergence 2024
Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse
Simon Petzinna¹, Jim Küppers², Benedikt Schemmer², Anna Kernder³, Claus Juergen Bauer¹, Pantelis Karakostas¹, Denada Bruci³, Adina Morar³, Anja Winklbauer², Markus Essler² and Valentin S. Schäfer², ¹Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, Bonn, Germany, ²University Hospital Bonn, Bonn, Germany, ³University Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
Background/Purpose: Vascular adhesion protein-1 (VAP-1) is a transmembrane adhesion molecule with oxidative deamination functionality, which is expressed in vascular smooth muscle cells and endothelial cells.…
Abstract Number: 1896 • ACR Convergence 2024
The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
Priyanka Chandratre¹, Joht Chandan², Ben Hammond³, Rasiah Thayakaran³, Samuel Cusworth³, Nicola Adderley³ and Deva Situnayake⁴, ¹The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, ²Institute of Applied Health Research, Birmingham, United Kingdom, ³Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ⁴Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom
Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…

« Previous Page
1
…
4
5
6
7
8
…
35
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].